Cytophage Technologies (TSXV:CYTO) Total Payout Yield % : -8.86 (As of Jun. 10, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Cytophage Technologies's current Total Payout Yield % is -8.86%.

Cytophage Technologies Total Payout Yield % Historical Data

The historical data trend for Cytophage Technologies's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Total Payout Yield % Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Total Payout Yield %

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Payout Yield %	Get a 7-Day Free Trial			-	-	-	-	-38.36

Competitive Comparison of Cytophage Technologies's Total Payout Yield %

For the Biotechnology subindustry, Cytophage Technologies's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Total Payout Yield % falls into.

Cytophage Technologies Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Cytophage Technologies's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	0
	=	N/A%

Cytophage Technologies's annualized Total Payout Yield % for the quarter that ended in Mar. 2024 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	2.5	+	0)	*	4	/	26.070399
	=	-38.36%

Cytophage Technologies Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Cytophage Technologies Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.